In fact, the price of such vouchers has been climbing steadily in recent months, according to public disclosures surrounding ...

Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...

The Priority Review Voucher (PRV) program is designed to incentivize rare disease drug development.

U.S. President Biden signed a bill last Thursday postponing the sunset date of the rare pediatric disease Priority Review Voucher (PRV) program from September 30, 2024, to December 20, 2024. The bill, ...